Last reviewed · How we verify
SB206 10.3% berdazimer
Berdazimer is a nitric oxide-releasing topical agent that generates nitric oxide to exert antimicrobial and anti-inflammatory effects on skin lesions.
Berdazimer is a nitric oxide-releasing topical agent that generates nitric oxide to exert antimicrobial and anti-inflammatory effects on skin lesions. Used for Molluscum contagiosum (topical treatment), Other viral skin infections.
At a glance
| Generic name | SB206 10.3% berdazimer |
|---|---|
| Also known as | SB206 12% berdazimer sodium |
| Sponsor | Novan, Inc. |
| Drug class | Nitric oxide-releasing topical agent |
| Target | Nitric oxide donor (non-receptor mediated) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Berdazimer is a diazeniumdiolate compound that releases nitric oxide when applied topically. Nitric oxide has broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, while also reducing inflammation and promoting wound healing. This mechanism makes it suitable for treating various viral skin infections.
Approved indications
- Molluscum contagiosum (topical treatment)
- Other viral skin infections
Common side effects
- Application site irritation
- Application site erythema
- Application site pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |